Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction
<p>Abstract</p> <p>Background</p> <p>Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-06-01
|
| Series: | Thrombosis Journal |
| Online Access: | http://www.thrombosisjournal.com/content/6/1/7 |